<DOC>
	<DOCNO>NCT01283776</DOCNO>
	<brief_summary>A phase II clinical study assess efficacy post-transplantation cyclophosphamide single-agent GvHD prophylaxis allogeneic hematopoietic stem cell transplantation patient multiple myeloma lymphoma describe influence modify immunosuppression concept relapse rate , minimal residual disease , immune reconstitution chimerism .</brief_summary>
	<brief_title>Cyclophosphamide Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Patients multiple myeloma , NonHodgkin 's lymphoma Hodgkin 's disease allogeneic stem cell transplantation reduce intensity conditioning Written inform consent No uncontrolled infection Severe organ dysfunction define : Cardiac leave ventricular ejection fraction ( LVEF ) less 35 % diffuse lung capacity ( DLCO ) less 40 % total lung capacity ( TLC ) less 40 % forced expiratory volume ( FEV1 ) less 40 % total bilirubin &gt; 3mg/dl creatinineclearance less 40 ml/min pregnancy breast feed participation experimental drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>